What Klacid MR Treats: Main Uses and Benefits

Klacid MR (Clarithromycin Modified-Release) is a macrolide antibiotic primarily used to help address bacterial infections, which assists with easing the symptoms related to physical discomfort and heightened physiological activity. This medication is commonly used across domains involving significant symptom expression.

It is applied in clinical settings that involve acute or unstable symptom patterns, addressing conditions characterized by periods of heightened symptoms such as community-acquired pneumonia, acute exacerbations of bronchitis, sinusitis, and otitis media. Klacid MR is also a part of multi-drug therapy for peptic ulcer disease caused by H. pylori, and is considered relevant for managing uncomplicated skin and soft tissue infections.

When symptom clusters like fever, cough, sore throat, swelling, and pain become more noticeable, this medicine provides supportive relief that may assist with maintaining a sense of stability during symptomatic periods. Its use supports the patient in contexts involving inflammatory or irritative processes.

---

Quick Fact: Focus on Symptoms of Respiratory Distress
Klacid MR assists with managing acute symptoms of bacterial chest infections, such as cough and fever, which contributes to improved comfort and helps ease the overall symptom burden.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Klacid MR (Clarithromycin Modified-Release)

Klacid MR is officially indicated for use in adults and adolescents 12 years of age and older. The Modified-Release (MR) tablet formulation is not recommended for children under 12, as a different clarithromycin formulation is specified for that age group.

Regulatory documents establish several absolute contraindications (populations who must not use the medicine):

• Patients with known hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.
• Individuals with a history of QT prolongation or ventricular cardiac arrhythmias.
• Patients with uncorrected low potassium or low magnesium levels.
• Patients suffering from severe hepatic failure combined with severe renal impairment (creatinine clearance less than 30 mL/min), as the MR tablet dose cannot be adjusted.

Use requires caution in patients with impaired hepatic function and certain underlying cardiac conditions. Safety during pregnancy and lactation has not been established and use is therefore not advised unless necessary.

Klacid MR (Clarithromycin) is a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein transporter. This mechanism can significantly raise the blood levels of many co-administered medicines that are metabolized by these systems, increasing the risk of severe side effects.

Contraindicated Combinations

Concomitant use is strictly contraindicated with several medicines due to the risk of serious adverse reactions. This includes:

• HMG-CoA reductase inhibitors (Statins): Specifically Lovastatin and Simvastatin, due to a heightened risk of myopathy, including rhabdomyolysis.
• Ergot Alkaloids: Such as Ergotamine and Dihydroergotamine, due to the potential for acute ergot toxicity, characterized by vasospasm and ischemia.
• Selected Oral Medications: Including Astemizole, Cisapride, Domperidone, Pimozide, and Terfenadine, as co-administration may cause QT prolongation and life-threatening cardiac arrhythmias.
• Other Drugs: Including Lomitapide, Oral Midazolam, Colchicine (especially in patients with kidney or liver impairment), Ticagrelor, Ranolazine, and Ivabradine.

Caution Required

Caution and monitoring are essential when Klacid MR is used with Oral Anticoagulants (like Warfarin), requiring close management of INR. Dosage adjustment or monitoring is also required for certain Antiarrhythmics, Antipsychotics, and other CYP3A4-metabolized drugs. Use is generally not recommended in patients with uncorrected low blood potassium or magnesium, due to an increased risk of heart rhythm problems.

The action of Clarithromycin is highly specific, focused exclusively on disrupting the internal machinery essential for bacterial survival. The drug's mechanism is activated upon intracellular distribution of the active molecule.

---

Targeting the Bacterial Protein Factory

The fundamental mechanism involves the drug acting as a protein synthesis inhibitor. Clarithromycin binds reversibly to the 50S ribosomal subunit of susceptible bacteria, specifically obstructing the exit tunnel used by the microbe to manufacture its essential proteins. The molecular blockade inhibits the elongation of polypeptide chains, reducing the production of structural components and enzymes.

---

Cessation of Pathogen Growth and Proliferation

The immediate consequence of inhibited protein synthesis is the cessation of bacterial growth (bacteriostasis) and multiplication within tissues. By stopping the pathogen's ability to divide, the drug reduces the microbial load. This physiological effect shifts the dynamic of the microbial load, contributing to the overall resolution of the infection cascade.

---

Mechanistic Limitations: Resistance Mechanisms

The drug's mechanism is constrained by bacterial countermeasures, such as target site modification (genetic changes in the 23S rRNA that reduce drug binding) and active drug efflux (pumps that expel the drug from the cell). These biological processes prevent the effective concentration of Clarithromycin from being maintained at the 50S ribosomal target, circumventing the mechanism's intended blockade.

The administration of Klacid MR is strictly defined by its Modified-Release (MR) formulation, which dictates specific rules for its ingestion and use over time. The medicine is intended for oral administration only. The standard dosing regimen for adults and adolescents aged 12 years and older is typically 1000 mg (one gram) taken once daily. In some cases, a starting dose of 500 mg once daily may be used, with the dosage increasing to 1000 mg for more severe infections.

To ensure the controlled release mechanism functions as intended, the tablet must be taken with food and should be swallowed whole. It is crucial that the tablet is not chewed, broken, or crushed at any point, as this would compromise the modified-release system. The treatment course is generally a short-term plan, lasting for a duration ranging from 7 to 14 days, based on the protocol established by the prescribing authority.

Special attention is given to certain patient groups. The modified-release tablet is not recommended for use in children younger than 12 years; in this population, an immediate-release liquid formulation is typically substituted. Similarly, the MR form is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min), as the fixed-dose format prevents the necessary dose reduction.

Research Evidence / Overview of Studies for Klacid MR

Evidence for Respiratory Tract Infections

Research regarding Klacid MR in respiratory conditions has focused on short-term clinical trials. These studies, often involving randomized comparisons against other treatments, were designed to explore the evaluation of the drug in conditions characterized by acute episodes in adult and adolescent populations.

For Acute Exacerbation of Chronic Bronchitis (AECB), studies explored how symptoms evolved in the observed populations. Research examined the measurement of a specific clinical status and the rates of bacteriologic clearance for studied bacteria. Similarly, for Community-Acquired Pneumonia (CAP), randomized trials monitored physiological strain and assessed measurements of symptom evolution in adult patients.

Evidence for Other Key Indications

Research also examined Acute Maxillary Sinusitis, where studies focused on measured changes in sinus-related discomfort. The active ingredient, Clarithromycin, was also studied for use as part of multi-drug regimens for conditions associated with H. pylori infection, where the primary outcome monitored was the rate of bacterial clearance (eradication).

Follow-up and Uncertainty

A consistent finding across the research base is that follow-up durations were limited, and the durability of any reported changes is not fully established. Evidence is limited regarding the evaluation of the Modified-Release formulation in certain groups, such as pediatric populations for respiratory conditions. Furthermore, the variability in bacterial resistance across different regions was observed in some studies to be a significant factor that can affect the generalizability of research findings. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

1. MedlinePlus: Clarithromycin
2. Clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis (AECB): ClinicalTrials.gov Study Record

Common questions about Klacid MR (FAQ)

---

Q: Do I need to avoid any specific foods while taking Klacid MR?

Official product information states that Klacid MR must be taken with food for the modified-release mechanism to work correctly. This practice supports the desired function of the modified-release tablet. However, official regulatory documents do not list specific foods or drinks that must be avoided while taking this medicine.

---

Q: Can I take Klacid MR if I also take a blood pressure medication?

The use of Klacid MR with certain blood pressure medicines is noted as requiring caution. Medicines that are metabolized by the CYP3A4 enzyme (like some Calcium Channel Blockers) may have increased blood levels when taken alongside Klacid MR. Official warnings advise close monitoring by a healthcare provider if these medicines are used together.

---

Q: Is Klacid MR used for sinusitis or ear infections?

Official product information states that the active ingredient in Klacid MR is used for upper respiratory tract infections, including conditions such as sinusitis. The active substance is also indicated for Acute Otitis Media, commonly known as an ear infection.

---

Q: What are the signs of a serious allergic reaction to Klacid MR?

Regulatory documents emphasize the risk of serious allergic reactions. Reported signs of a serious allergic reaction include difficulty breathing and swelling of the face, lips, tongue, or throat. Severe skin reactions, such as blistering or peeling skin, are also described as serious concerns.

---

Q: Does Klacid MR cause headaches or dizziness?

Headache is reported as a common side effect of Klacid MR. In addition, official product information indicates that dizziness and disorientation are other reported side effects that may occur.

---

Q: Does Klacid MR cause diarrhea, and if so, is it serious?

Diarrhoea is one of the most common side effects reported with Klacid MR. Official warnings indicate that diarrhoea that is watery, bloody, or severe may be a sign of a serious condition called C. difficile-associated diarrhoea. This serious risk is noted in official warnings as a condition that requires medical review.

---

Q: What is the purpose of the enteric coating on some Klacid tablets?

The Klacid MR tablet is engineered using a Modified-Release formulation, which is designed to deliver the medicine slowly over an extended period. This design helps to maintain a consistent drug level and has been associated with fewer episodes of gastrointestinal side effects compared to the immediate-release form.

---

Q: What does the term 'macrolide' mean in relation to Klacid MR?

The term macrolide describes the class of antibiotic to which clarithromycin belongs. These types of antibiotics work by targeting the internal machinery of susceptible bacteria, specifically by stopping them from creating the essential proteins needed for their growth and multiplication.

---

Q: Can Klacid MR be taken by someone with a penicillin allergy?

Official regulatory documentation lists a contraindication only for known hypersensitivity to clarithromycin or any other macrolide antibiotic. Official contraindications do not specifically list penicillin allergy as a sole reason to avoid the medicine.

---

Q: Can Klacid MR be used to treat dental infections?

Research evidence supports the use of the active ingredient in Klacid MR for various bacterial infections. Official indications include the treatment of skin and soft tissue infections, which includes some infections that affect the mouth or dental area.

---

Q: Is there a link between Klacid MR and hearing problems?

Hearing problems, including hearing loss (ototoxicity) and tinnitus (ringing in the ears), have been reported in official product information as potential side effects. Regulatory documents often describe these effects as potentially reversible.

---

Q: Does Klacid MR interact with common pain relievers like paracetamol?

According to the official drug interaction checkers and product information, no clinically significant or major drug interactions have been reported between clarithromycin and the common pain reliever paracetamol (acetaminophen).

---

Q: Is Klacid MR safe for older patients?

Clarithromycin is used in older patients. Official product information advises that caution should be exercised for this population. Since kidney function can change with age, regulatory documents mention that dosage modification may be considered by a prescriber.

---

Q: Can I drink alcohol while I am on Klacid MR?

Official regulatory documentation does not report a direct, negative pharmacological interaction between clarithromycin and alcohol.

---

Q: What research has been done on Klacid MR for skin infections?

Research evidence supports the official use of Klacid MR for skin and soft tissue infections caused by susceptible microorganisms. These studies are conducted to explore the efficacy and safety of the drug for these specific conditions.

---

Q: What should I do if the side effects of Klacid MR are bothersome?

Official regulatory guidance suggests that patients contact a doctor or pharmacist if side effects become bothersome or severe.

---

Q: Can Klacid MR affect the effectiveness of oral contraceptives?

Official information indicates that clarithromycin may affect the blood levels and effectiveness of certain hormonal oral contraceptives. Regulatory information notes that medical review is needed to determine if alternative contraception is appropriate during treatment.

---

Q: Can Klacid MR interact with herbal remedies like St. John's wort?

St. John's wort is known to interact with medicines that rely on the same liver enzymes (CYP3A4) as clarithromycin. Official warnings advise that because St. John's wort can affect the metabolism of Klacid MR, its concurrent use requires discussion with a healthcare provider.

---

Q: Are changes in mood a reported side effect of Klacid MR?

Rare side effects reported in official documentation include changes in mood or mental state. These effects may include conditions such as anxiety, confusion, and depression.

---

Q: Can Klacid MR make you feel tired or drowsy?

Official product information states that unusual tiredness or weakness is a reported side effect of Klacid MR.

How to Store and Dispose of Klacid MR

The storage and disposal of Klacid MR (clarithromycin modified-release) must adhere strictly to regulatory requirements to maintain drug quality and ensure safety.

---

Storage Requirements

Klacid MR tablets must be stored at controlled room temperature, typically mathbf20 C to mathbf25 C (68 F to 77 F). The medicine must be kept from freezing and stored away from heat, moisture, and direct light.

The product should remain in the tightly closed container it came in. A mandatory safety rule is to keep out of the sight and reach of children.

Disposal Instructions

Do not use the medicine past the expiry date stated on the package. Unused or expired Klacid MR must not be disposed of via wastewater or household waste. The official procedure is to ask a pharmacist for guidance on how to safely throw away medicines no longer in use.